"Novel Polymorphic Forms Of Tolvaptan"

Enaltec Labs Private Limited
Granted App No 1320/MUM/2011 Patent 377913 Chemical

Patent information

IP India · live record
Application number
1320/MUM/2011
Filing date
26 April 2011
Status
Granted
Legal status
Ceased
Publication number
49/2012
Publication type
INA
Invention field
Chemical
Patent number
377913
Grant date
27 September 2021
Next renewal due
26 April 2024Overdue

Abstract

The present invention relates to novel crystalline polymorphs of tolvaptan hereinafter referred as crystalline form II and cryatalline form III. the present invention further relates to a process of preparing crystalline form 11 and crystalline form III of tolvaptan and pharmaceutical composition thereof.

Applicants

1
India
ENALTEC LABS PRIVATE LIMITED 17TH FLOOR, KESAR SOLITAIRE, PLOT NO.5, SECTOR-19, SANPADA, NAVI MUMBAI MAHARASHTRA, INDIA. PIN CODE: 400705

Inventors

5
India
SIVA KUMAR VENKATA BOBBAENALTEC LABS PRIVATE LIMITED, PLOT NO. W-59 A, ADDL MIDC, AMBERNATH, DIST-THANE-421506, MAHARASHTRA, INDIA
India
ESWARA RAO KODALIENALTEC LABS PRIVATE LIMITED, PLOT NO. W-59 A, ADDL MIDC, AMBERNATH, DIST-THANE-421506, MAHARASHTRA, INDIA
India
GIRISH BANSILAL PATELENALTEC LABS PRIVATE LIMITED, PLOT NO. W-59 A, ADDL MIDC, AMBERNATH, DIST-THANE-421506, MAHARASHTRA, INDIA
India
SANJAY DASHRATH VAIDYAENALTEC LABS PRIVATE LIMITED, PLOT NO. W-59 A, ADDL MIDC, AMBERNATH, DIST-THANE-421506, MAHARASHTRA, INDIA
India
ALOK PRAMOD TRIPATHIENALTEC LABS PRIVATE LIMITED, PLOT NO. W-59 A, ADDL MIDC, AMBERNATH, DIST-THANE-421506, MAHARASHTRA, INDIA

Claims

10
1 A compound which is a crystalline form II of tolvaptan having substantially the same X-ray diffraction pattern as depicted in Figure 1 -
2 The compound of claim no. 1, is further characterized by X-ray diffraction pattern having peaks at 11.6, 12.2, 13.3, 13.8, 16.2, 19.7, 21.3, 22.3, 23.2, 25.6 ± 0.2 degrees two theta.
3 A process of preparing crystalline form II comprising crystallization of tolvaptan crystalline form I in a mixture of alcohol and water solvents.
4 Tne process according to claim no. 3, wherein crystalline form II of tolvaptan is formed by dissolving tolvaptan crystalline form I in mixture of alcohol such as methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, pentanol or mixture(s) thereof and water solvents at 55-75°C and then resulting solution may be cooled gradually up to 25°C and then resulting solids may be filtered, washed with water and dried at a temperature in the range of 40-60°C for a period of 1 hour to 8 hours under reduced pressure.
5 A compound which is a crystalline form III of tolvaptan having substantially the same X-ray diffraction pattern as depicted in Figure 2.
6 The compound of claim no. 6, is further characterized by X-ray diffraction pattern having peaks at 7.5, 9.2, 11.0, 13.5, 14.3, 17.8, 19.2, 20.3, 24.3, 26.9, 28.1 ± 0.2 degrees two theta.
7 A process of preparing crystalline form III comprising crystallization of tolvaptan crystalline form I or tolvaptan crystalline form II in an alcohol solvent in the presence of aqueous solution of alkali metal hydroxide.
8 The process according to claim no. 8, wherein crystalline form III of tolvaptan is formed by treating a solution of tolvaptan crystalline form I or form II in an alcohol solvent such as methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, pentanol or mixture(s) thereof with aqueous alkali metal hydroxide such as sodium hydroxide, potassium hydroxide or lithium hydroxide at a temperature in the range of 25°C to 30°C for a period of 30 minutes to 4 hours and then resulting solids may be filtered, washed with water and dried at a temperature in the range of 35°C to 70°C for a period of 30 minutes to 4 hours under reduced pressure.
9 A pharmaceutical composition of tolvaptan comprising crystalline form II of tolvaptan and pharmaceutically acceptable excipients.
10 A pharmaceutical composition of tolvaptan comprising crystalline form III of tolvaptan and pharmaceutically acceptable excipients.

Specification

Show full textCollapse

FORM 2 THE PATENT ACT, 1970 (39 of 1970) & The Patents Rules, 2003 COMPLETE SPECIFICATION (See section 10 and rule 13) Title of the invention "NOVEL POLYMORPHIC FORMS OF TOLVAPTAN." Enaltec Labs Pvt. Ltd. an Indian Company, having its Registered Office at 17,thFloor, Kesar Solitaire, Plot No.5 Sector-19, Sanpada, Navi Mumbai Maharashtra, India. Pin Code: 400705 1. The following specification particularly describes the invention and the manner in which it is to be performed.

NOVEL POLYMORPHIC FORMS OF TOLVAPTAN FIELD OF THE INVENTION: The present invention relates to novel crystalline polymorphs of tolvaptan hereinafter referred as crystalline form II and crystalline form III. The present invention further relates to a process of preparing crystalline form II and crystalline form III of tolvaptan and pharmaceutical composition thereof. BACKGROUND OF THE INVENTION: Tolvaptan is chemically (±)-4'-[(7-chloro-2, 3, 4. 5-tetrahydro-5-hydroxy-1H-l-benzazepin-1-yl) carbonyl]-o-tolu-m-toluidide and is known from U.S. Patent No. 5,258,510 and is represented by compound of structural formula I.

Formula I Tolvaptan has been approved in USA and sold in market under the proprietary name SAMSCA. It is a selective vasopressin V2-receptor antagonist indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia [serum sodium < 125 m Eq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction], including patients with heart failure, cirrhosis, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH). U.S. Patent No. 5.258.510 describes a process of preparing amorphous tolvaptan by the crystallization in methanol solvent.

U.S. patent publication no. 2007/0185323 describes crystallization of tolvaptan in methanol / ether solvents. The resulting product is amorphous in nature. U.S. patent publication no. 2009/0306369 describes crystallization of tolvaptan in mixture of methanol / water solvents and the resulting crystalline form is characterized by data selected from a group consisting of: a powder XRD pattern having peaks at about 4.7, 15.4, 18.7, 21.7, 23.5 degrees 2-theta. which is hereinafter referred as crystalline form I. Polymorphism, the occurrence of different crystal forms, is a property of some molecules and molecular complexes. A single molecule may give rise to a variety of crystalline forms having distinct crystal structures and physical properties like melting point, x-ray diffraction pattern, infrared absorption fingerprint, and solid state NMR spectrum. One crystalline form may give rise to thermal behavior different from that of another crystalline form. Thermal behavior can be measured in the laboratory by such techniques as capillary melting point, thermogravimetric analysis ("TGA"), and differential scanning calorimetry ("DSC) as well as by content of solvent in the crystalline form, which have been used to distinguish polymorphic forms. The difference in the physical properties of different crystalline forms results from the orientation and intermolecular interactions of adjacent molecules or complexes in the bulk solid. Accordingly, polymorphs are distinct solids sharing the same molecular formula yet having distinct advantageous physical properties compared to other crystalline forms of the same compound or complex. One of the most important physical properties of pharmaceutical compounds is their solubility in aqueous solutions, particularly their solubility in the gastric juices of a patient. For example, where absorption through the gastrointestinal tract is slow, it is often desirable for a drug that is unstable to conditions in the patient's stomach or intestine to dissolve slowly so that it does not accumulate in a deleterious environment.

Different crystalline forms or polymorphs of the same pharmaceutical compounds can and reportedly do have different aqueous solubilities. The discovery of new polymorphic forms and solvates of a pharmaceutically useful compound provides a new opportunity to improve the performance characteristics of a pharmaceutical product. It enlarges the repertoire of materials that a formulation scientist has available for designing, for example, a pharmaceutical dosage form of a drug with a targeted release profile or other desired characteristic. Therefore, there is a need in the art for developing additional solid state forms of tolvaptan. The present applicant of the patent has surprisingly found new crystalline polymorphic forms of tolvaptan, which is designated as form II and form III. SUMMARY OF THE INVENTION: A first aspect of the present invention is to provide novel polymorphs of tolvaptan hereinafter referred as crystalline form II and crystalline form III of tolvaptan. A second aspect of the present invention is to provide a pharmaceutical composition comprising crystalline form II or crystalline form III of tolvaptan. Another aspect of the present invention is to provide a process of preparing crystalline form II comprising crystallization of tolvaptan crystalline form I in a mixture of alcohol and water solvents. Another aspect of the present invention is to provide a process of preparing crystalline form III comprising crystallization of tolvaptan crystalline form I or tolvaptan crystalline form II in an alcohol solvent in the presence of aqueous solution of alkali metal hydroxide.

DETAIL DESCRIPTION OF THE INVENTION: A crystalline form II of tolvaptan may be characterized by X-ray diffraction pattern having peaks at 11.6, 12.2, 13.3, 13.8, 16.2, 19.7, 21.3, 22.3, 23.2, 25.6± 0.2 degrees two theta. A crystalline form 11 of tolvaptan may be characterized by X-ray diffraction pattern as depicted in Figure 1. A crystalline form III of tolvaptan may be characterized by X-ray diffraction pattern having peaks at 7.5, 9.2, 11.0, 13.5, 14.3, 17.8, 19.2,20.3,24.3,26.9,28.1 ± 0.2 degrees two theta. A crystalline form III of tolvaptan may be characterized by X-ray diffraction pattern as depicted in Figure 2. Tolvaptan used for the present invention may be formed by methods disclosed in the art such as those described in U.S. Patent nos. 5,258.510; U.S. patent publication no. 2007/0185323, 2009/0306369 which are incorporated herein by reference only. The crystalline form II of tolvaptan may be formed by dissolving tolvaptan crystalline form I in mixture of alcohol and water solvents at 55-75°C and then resulting solution may be cooled gradually up to 25°C and then resulting solids may be filtered, washed with water and dried at a temperature in the range of 40-60°C for a period of 1 hour to 8 hours under reduced pressure. The examples of alcohol solvents may include methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, pentanol or mixture(s) thereof. The crystalline form III of tolvaptan may be formed by treating a solution of tolvaptan crystalline form 1 or form II in an above mentioned alcohol solvent with aqueous alkali

metal hydroxide at a temperature in the range of 25°C to 30°C for a period of 30 minutes to 4 hours and then resulting solids may be filtered, washed with water and dried at a temperature in the range of 35°C to 70°C for a period of 30 minutes to 4 hours under reduced pressure. The examples of an alkali metal hydroxide may be selected from the group comprising of sodium hydroxide, potassium hydroxide or lithium hydroxide. A pharmaceutical composition of tolvaptan comprising crystalline form II of tolvaptan and pharmaceutically acceptable excipients A pharmaceutical composition of tolvaptan comprising crystalline form III of tolvaptan and pharmaceutically acceptable excipients BRIEF DESCRIPTION OF THE DRAWINGS: Figure 1 depicts X-ray diffraction pattern of crystalline form II of tolvaptan. Figure 2 depicts X-ray diffraction pattern of crystalline form III of tolvaptan. XRD diffraction measurement was performed on X-Ray powder diffractometer Bruker D8 Advance powder diffractometer with the detector Lynxeye (Bruker). The analysis conditions were as follows: Scan range [°2-theta]: 2-39.98; Scan mode: Continuous; Step size [°2-theta]: 0.0170°; Scan step time[s]: 51.04 seconds; Sample spin: 15 rpm; Sample holder: glass; Measurement Temperature [°C]: 25 Anode Material: Cu K-Alpha[A]: 1.54060

Prior to analysis, the samples were gently ground by means of mortar and pestle in order to obtain a fine powder. The sample might be mixed with n-dodecane in order to avoid the environment contamination by airborne particles coming from the powder. The ground sample or its suspension with n-dodecane was adjusted into a cavity of the sample holder and the surface of the sample was smoothed by means of a cover glass. The advantages of Tolvaptan crystalline form II and III are as follows: 1. Free-flowing nature 2. Non hygroscopic nature 3. Free from residual solvents like alcohols. 4. Easy to formulate into oral tablet dosage form. 5. Low static charge EXAMLES: In the following examples, the preferred embodiments of the present invention are described only by way of illustrating the processes of the invention. However, these are not intended to limit the scope of the present invention in any way. Example 1: Preparation of crystalline form II of tolvaptan Tolvaptan crystalline form I (10gm) was dissolved in mixture of methanol (90ml) and water (10ml) at 55-75°C and resulting transparent solution was stirred 10 minutes at 55- 75°C and then it was cooled to 25°C. The resulting solids were filtered, washed with water (10ml) and dried at 50°C for 1 hour under reduced pressure to get title compound. Yield: 9.8gm Purity: 99.86% (By HPLC) XRD: As depicted in Figure 1

Example 2: Preparation of crystalline form III of tolvaptan A solution of tolvaptan crystalline form I (10gm) in ethanol (150ml) was added aqueous sodium hydroxide solution (5%, 150ml) and the resulting solution was stirred for 2 hours at 25oC and then resulting solids were filtered, washed with water (10ml) and dried at 50- 55°C for a period of 2 hours under reduced pressure to get title compound. Yield: 9.7gm Purity: 99.93% (By HPLC) XRD: As depicted in Figure 2 Example 3: Preparation of crystalline form III of tolvaptan A solution of tolvaptan crystalline form II (5gm) in n-butanol (75ml) was added aqueous potassium hydroxide solution (2.5%, 75ml) and the resulting solution was stirred for 3 hours at 25°C and then resulting solids were filtered, washed with water (5ml) and dried at 55°C for a period of 2 hours under reduced pressure to get title compound. Yield: 4.8gm Purity: 99.95% (By HPLC) XRD: As depicted in Figure 2

WE CLAIM: 1. A compound which is a crystalline form II of tolvaptan having substantially the same X-ray diffraction pattern as depicted in Figure 1 - 2. The compound of claim no. 1, is further characterized by X-ray diffraction pattern having peaks at 11.6, 12.2, 13.3, 13.8, 16.2, 19.7, 21.3, 22.3, 23.2, 25.6 ± 0.2 degrees two theta. 3. A process of preparing crystalline form II comprising crystallization of tolvaptan crystalline form I in a mixture of alcohol and water solvents. 4. Tne process according to claim no. 3, wherein crystalline form II of tolvaptan is formed by dissolving tolvaptan crystalline form I in mixture of alcohol such as methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, pentanol or mixture(s) thereof and water solvents at 55-75°C and then resulting solution may be cooled gradually up to 25°C and then resulting solids may be filtered, washed with water and dried at a temperature in the range of 40-60°C for a period of 1 hour to 8 hours under reduced pressure. 5. A compound which is a crystalline form III of tolvaptan having substantially the same X-ray diffraction pattern as depicted in Figure 2.

6. The compound of claim no. 6, is further characterized by X-ray diffraction pattern having peaks at 7.5, 9.2, 11.0, 13.5, 14.3, 17.8, 19.2, 20.3, 24.3, 26.9, 28.1 ± 0.2 degrees two theta. 7. A process of preparing crystalline form III comprising crystallization of tolvaptan crystalline form I or tolvaptan crystalline form II in an alcohol solvent in the presence of aqueous solution of alkali metal hydroxide.

8. The process according to claim no. 8, wherein crystalline form III of tolvaptan is formed by treating a solution of tolvaptan crystalline form I or form II in an alcohol solvent such as methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, pentanol or mixture(s) thereof with aqueous alkali metal hydroxide such as sodium hydroxide, potassium hydroxide or lithium hydroxide at a temperature in the range of 25°C to 30°C for a period of 30 minutes to 4 hours and then resulting solids may be filtered, washed with water and dried at a temperature in the range of 35°C to 70°C for a period of 30 minutes to 4 hours under reduced pressure. 9. A pharmaceutical composition of tolvaptan comprising crystalline form II of tolvaptan and pharmaceutically acceptable excipients. 10. A pharmaceutical composition of tolvaptan comprising crystalline form III of tolvaptan and pharmaceutically acceptable excipients.

Documents

Sign in to open
Orders
Section
Application documents
1 ABSTRACT1.jpg 10 Aug 2018
2 1320-MUM-2011-Other Patent Document-130115.pdf 10 Aug 2018
3 1320-MUM-2011-FORM 5(23-4-2012).pdf 10 Aug 2018
4 1320-mum-2011-form 3(26-4-2011).pdf 10 Aug 2018
5 1320-mum-2011-form 2(title page)-(provisional)-(26-4-2011).pdf 10 Aug 2018
6 1320-MUM-2011-FORM 2(TITLE PAGE)-(23-4-2012).pdf 10 Aug 2018
7 1320-mum-2011-form 2(provisional)-(26-4-2011).pdf 10 Aug 2018
8 1320-MUM-2011-FORM 2(23-4-2012).pdf 10 Aug 2018
9 1320-MUM-2011-Form 18-130115.pdf 10 Aug 2018
10 1320-mum-2011-form 1(26-4-2011).pdf 10 Aug 2018
11 1320-mum-2011-drawing(26-4-2011).pdf 10 Aug 2018
12 1320-MUM-2011-DRAWING(23-4-2012).pdf 10 Aug 2018
13 1320-mum-2011-description(provisional)-(26-4-2011).pdf 10 Aug 2018
14 1320-MUM-2011-DESCRIPTION(COMPLETE)-(23-4-2012).pdf 10 Aug 2018
15 1320-mum-2011-correspondence(26-4-2011).pdf 10 Aug 2018
16 1320-MUM-2011-CORRESPONDENCE(23-4-2012).pdf 10 Aug 2018
17 1320-MUM-2011-CLAIMS(23-4-2012).pdf 10 Aug 2018
18 1320-MUM-2011-ABSTRACT(23-4-2012).pdf 10 Aug 2018
19 1320-MUM-2011-FER.pdf 20 May 2019
20 1320-MUM-2011-Marked Copy-071119.pdf 09 Nov 2019
21 1320-MUM-2011-Form 2(Title Page)-071119.pdf 09 Nov 2019
22 1320-MUM-2011-Examination Report Reply Recieved-071119.pdf 09 Nov 2019
23 1320-MUM-2011-Drawing-071119.pdf 09 Nov 2019
24 1320-MUM-2011-Claims-071119.pdf 09 Nov 2019
25 1320-MUM-2011-Amended Pages Of Specification-071119.pdf 09 Nov 2019
26 1320-MUM-2011-Abstract-071119.pdf 09 Nov 2019
27 1320-MUM-2011-PatentCertificate27-09-2021.pdf 27 Sep 2021
28 1320-MUM-2011-IntimationOfGrant27-09-2021.pdf 27 Sep 2021
29 1320-MUM-2011-US(14)-HearingNotice-(HearingDate-07-09-2021).pdf 03 Oct 2021
30 1320-MUM-2011-REPLY TO HEARING REPORT-160921.pdf 03 Oct 2021
31 1320-MUM-2011-POWER OF ATTORNEY-60921.pdf 03 Oct 2021
32 1320-MUM-2011-MARKED COPY-60921.pdf 03 Oct 2021
33 1320-MUM-2011-FORM5-60921.pdf 03 Oct 2021
34 1320-MUM-2011-FORM3-60921.pdf 03 Oct 2021
35 1320-MUM-2011-FORM2(TITLE PAGE)-60921.pdf 03 Oct 2021
36 1320-MUM-2011-CLAIM-160921.pdf 03 Oct 2021
37 1320-MUM-2011-FORM1-60921.pdf 18 Oct 2021
38 377913-Form 4-230522.pdf 24 May 2022
39 377913-Correspondence (Renewal)-230522.pdf 24 May 2022
40 377913-Form 4-171023.pdf 30 Oct 2023
41 377913-CORRESPONDENCE-171023.pdf 30 Oct 2023
42 377913-CORRESPONDENCE (RENEWAL)-171023.pdf 30 Oct 2023
Search strategy
1search_17-05-2019.pdf

ERegister / renewals

Ceased
3rd Renewed 23 May 2022 Period 26 Apr 2013 – 26 Apr 2014 · CBR 13163 · Certificate 14424 ₹4,400
4th Renewed 23 May 2022 Period 26 Apr 2014 – 26 Apr 2015 · CBR 13163 · Certificate 14424 ₹4,400
5th Renewed 23 May 2022 Period 26 Apr 2015 – 26 Apr 2016 · CBR 13163 · Certificate 14424 ₹4,400
6th Renewed 23 May 2022 Period 26 Apr 2016 – 26 Apr 2017 · CBR 13163 · Certificate 14424 ₹4,400
7th Renewed 23 May 2022 Period 26 Apr 2017 – 26 Apr 2018 · CBR 13163 · Certificate 14424 ₹13,200
8th Renewed 23 May 2022 Period 26 Apr 2018 – 26 Apr 2019 · CBR 13163 · Certificate 14424 ₹13,200
9th Renewed 23 May 2022 Period 26 Apr 2019 – 26 Apr 2020 · CBR 13163 · Certificate 14424 ₹13,200
10th Renewed 23 May 2022 Period 26 Apr 2020 – 26 Apr 2021 · CBR 13163 · Certificate 14424 ₹13,200
11th Renewed 23 May 2022 Period 26 Apr 2021 – 26 Apr 2022 · CBR 13163 · Certificate 14424 ₹26,400
12th Renewed 23 May 2022 Period 26 Apr 2022 – 26 Apr 2023 · CBR 13163 · Certificate 14424 ₹26,400
13th Renewed 17 Oct 2023 Period 26 Apr 2023 – 26 Apr 2024 · CBR 42207 · Certificate 42100 ₹26,400